Diabetes lures pharma to the Gulf

Share this article:

Diabetes is a growing problem and pharmaceutical opportunity in Saudi Arabia. The Wall Street Journal outlines the health crisis that is increasingly visible during mall walks that double as a respite from the heat and a time to mingle over fast food.

The Journal also notes that governments in the Gulf have offered a mix of financial incentives to coax businesses to take manufacturing local, and that companies like Merck KGaA have partnered with local producers as a way of getting a foothold in the market.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.